During Friday’s current trade, Shares of Amazon.com Inc. (NASDAQ:AMZN), surged 14.59%, and is now trading at $446.89, hitting its highest level.
Amazon.com, declared financial results for its first quarter ended March 31, 2015.
Operating cash flow raised 47% to $7.84 billion for the trailing twelve months, contrast with $5.35 billion for the trailing twelve months ended March 31, 2014. Free cash flow raised to $3.16 billion for the trailing twelve months, contrast with $1.49 billion for the trailing twelve months ended March 31, 2014.
Common shares outstanding plus shares underlying stock-based awards totaled 483 million on March 31, 2015, contrast with 476 million one year ago.
Net sales raised 15% to $22.72 billion in the first quarter, contrast with $19.74 billion in first quarter 2014. Not taking into account the $1.3 billion unfavorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales raised 22% contrast to first quarter 2014.
Operating income raised 74% to $255 million in the first quarter, contrast with operating income of $146 million in first quarter 2014.
Net loss was $57 million in the first quarter, or $0.12 per diluted share, contrast with net income of $108 million, or $0.23 per diluted share, in first quarter 2014.
Amazon.com, Inc. operates as an online retailer in North America and internationally. It operates in two segments, North America and International. The company serves consumers through retail Websites, such as amazon.com and amazon.ca, which primarily comprise merchandise and content purchased for resale from vendors and those offered by third-party sellers.
During morning trade, Shares of Mast Therapeutics, Inc. (NYSEMKT:MSTX), dropped 3.09%, and is now trading at $0.4999.
Mast Therapeutics, stated that patient enrollment in its pivotal EPIC study of its lead product candidate, vepoloxamer (MST-188), in sickle cell disease has surpassed the halfway point. Consistent with preceding guidance, the Company anticipates reporting top-line results in the first quarter of 2016.
“We are extremely happy to report that, as of yesterday, 205 patients had been randomized to the EPIC study,” stated Brian M. Culley, Chief Executive Officer. “Consistent with projections we set for ourselves more than 18 months ago, we remain on track to declare top-line data in the first quarter of 2016. Our clinical operations team has opened more than 70 sites in ten countries, with more than two-thirds of those sites located in the U.S. In the next few months, we will be opening new sites in at least four additional countries.”
“We have cultivated relationships with the sickle cell medical and patient communities and continued to add new sites, which has raised awareness about our study. As a result, we are seeing consistent growth in enthusiasm and enrollment,” stated Dr. Edwin L. Parsley, the Company’s Chief Medical Officer. “Of note, more than 70% of the EPIC sites have enrolled at least one subject and 75% of those sites have enrolled two or more subjects. A majority of patients have come from our U.S. sites and we believe that at the conclusion of EPIC, the majority of the study population will have come from the U.S.”
“Notably, although EPIC is open to patients aged 4-65, the average age of randomized patients is 14. We believe the potential benefits of vepoloxamer are not limited to age, but that younger patients may experience a more distinct crisis, providing the opportunity to assess differences across age groups. In addition, about 20% of the randomized patients are 18 and over. Exposures to vepoloxamer across a wide age range will provide safety and efficacy data supportive of a broad label,” continued Dr. Parsley.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases. The company’s lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction.
Shares of AT&T, Inc. (NYSE:T), during its Friday’s current trading session lost -0.34%, and is now trading at $34.12.
Today, AT&T, invested nearly $1.7 Billion in its best-in-class wireless network in Washington from 2012 to 2014. These investments are driving a wide range of upgrades to reliability, coverage, speed and performance for residents and business customers.
AT&T made 216 wireless network upgrades in Washington last year, counting 14 new cell towers, 33 wireless broadband upgrades, 141 new wireless high-speed Internet connections, and additional network capacity.
AT&T provides the nation’s most reliable 4G LTE network recently, covering more than 300 million Americans with 4G LTE service.** AT&T’s network also has the nation’s strongest LTE signal. During 2014, several cities in Washington were added to AT&T’s extensive LTE network, counting: Cashmere, Chelan, Leavenworth, Walla Walla, Waterville and Wenatchee.
AT&T Inc. provides telecommunications services in the United States and internationally. The company operates through two segments, Wireless and Wireline. The Wireless segment offers data and voice services, counting local, long-distance, and network access services, in addition to roaming services to youth, family, professionals, small businesses, government, and business customers.
Finally, Pandora Media, Inc. (NYSE:P), gained 3.90% Friday.
Pandora Media, declared financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Financial Results
Revenue: For the first quarter of 2015, total revenue was $230.8 million, a 19% year-over-year enhance on a GAAP basis and a 28% year-over-year enhance on a non-GAAP basis. Advertising revenue was $178.7 million, a 27% year-over-year enhance. Subscription and other revenue was $52.0 million, a 32% year-over-year enhance on a non-GAAP basis.
Adjusted EBITDA: For the first quarter of 2015, adjusted EBITDA was a loss of $20.9 million, a 7% year-over-year improvement. Adjusted EBITDA excludes $23.2 million in expense from stock-based compensation, $4.3 million of depreciation and amortization expense, $0.1 million of provision for income taxes and $0.2 million of other income.
Cash and Investments: For the first quarter of 2015, the Company ended with $481.3 million in cash and investments, contrast to $458.8 million at the end of the preceding quarter. Cash offered by operating activities was $27.0 million for the first quarter of 2015, contrast to $2.1 million used in operating activities in the same period of the preceding year.
Pandora Media, Inc. provides Internet radio services in the United States. The company allows listeners to create up to 100 personalized stations to access free music and comedy catalogs, in addition to offers Pandora One, a paid subscription service to listeners.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
